{"id":6342,"date":"2022-04-05T13:15:46","date_gmt":"2022-04-05T13:15:46","guid":{"rendered":"https:\/\/wilate.com\/ca\/?page_id=6342"},"modified":"2022-12-22T13:36:19","modified_gmt":"2022-12-22T13:36:19","slug":"tolerability","status":"publish","type":"page","link":"https:\/\/wilate.com\/ca\/tolerability\/","title":{"rendered":"Tolerability"},"content":{"rendered":"

Tolerability<\/h1>\n

Treatment with von Willebrand factor concentrates is generally well tolerated.1, 2<\/sup><\/strong><\/p>\n


\n<\/sup><\/strong>Rare cases of thromboembolic events or the development of alloantibodies have been reported with some von Willebrand factor concentrates.3, 4<\/sup> No thromboembolic events or inhibitory alloantibodies have been reported in clinical trials with wilate\u00ae<\/sup> in people with all von Willebrand disease types.5<\/sup><\/p>\n

Tolerability of wilate\u00ae<\/sup><\/h2>\n

Tolerability of wilate\u00ae<\/sup> has been demonstrated across 8 clinical trials in 155 patients with von Willebrand disease5 <\/sup>*<\/p>\n

With 28 treatment-related adverse events reported in
\n17 patients<\/em><\/p>\n

* Indication: Prevention and treatment of haemorrhage or surgical bleeding in von Willebrand disease (VWD), when desmopressin (DDAVP) treatment alone is ineffective or contra-indicated.<\/p>\n

Thromboembolic events<\/em><\/p>\n

Treatment-related deaths<\/em><\/p>\n

Inhibitory antibodies to von Willebrand factor<\/em><\/p>\n

Tolerability of wilate\u00ae<\/sup><\/h2>\n

Tolerability of wilate\u00ae<\/sup> was rated very good or good >99% of infusions6<\/sup><\/em><\/p>\n

Tolerability has been confirmed in over 15 years of experience in the real-world setting, with approximately 1.8 billion international units of wilate\u00ae<\/sup> distributed wordwide5<\/sup><\/em><\/p>\n

Tolerability of wilate\u00ae<\/sup><\/h2>\n

Information about on-demand treatment with wilate\u00ae<\/sup><\/p>\n


\nTreat on-demand
\n<\/a><\/p>\n

Surgical prophylaxis with wilate\u00ae<\/sup><\/p>\n


\nPrepare for surgery
\n<\/a><\/p>\n

wilate\u00ae<\/sup> physiological 1:1 activity ratio<\/p>\n


\nDosing
\n<\/a><\/p>\n

References<\/h4>\n
    \n
  1. Castaman G and Linari S J Blood Med<\/em> 2021; 12:165-75.<\/li>\n
  2. Federici AB and James P Acta Haematol<\/em> 2012; 128:88-99.<\/li>\n
  3. Rietveld IM et al. J Thromb Haemost<\/em> 2019; 17:99-109.<\/li>\n
  4. James PD et al. Blood<\/em> 2013; 122:636-40.<\/li>\n
  5. Octapharma, data on file.<\/li>\n
  6. Berntorp E et al. Haemophilia<\/em> 2009; 15:122-30.<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

    Tolerability Treatment with von Willebrand factor concentrates is generally well tolerated.1, 2 Rare cases of thromboembolic events or the development of alloantibodies have been reported with some von Willebrand factor concentrates.3, 4 No thromboembolic events or inhibitory alloantibodies have been reported in clinical trials with wilate\u00ae in people with all von Willebrand disease types.5 Tolerability […]<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"elementor_header_footer","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-6342","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"\nSafety and tolerability of vwd treatment<\/title>\n<meta name=\"description\" content=\"Treatment with von Willebrand factor concentrates is generally well tolerated. No thromboembolic events or inhibitory antibodies haven been reported.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/wilate.com\/ca\/tolerability\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Safety and tolerability of vwd treatment\" \/>\n<meta property=\"og:description\" content=\"Treatment with von Willebrand factor concentrates is generally well tolerated. No thromboembolic events or inhibitory antibodies haven been reported.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/wilate.com\/ca\/tolerability\/\" \/>\n<meta property=\"og:site_name\" content=\"WILATE CA\" \/>\n<meta property=\"article:modified_time\" content=\"2022-12-22T13:36:19+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/wilate.com\\\/ca\\\/tolerability\\\/\",\"url\":\"https:\\\/\\\/wilate.com\\\/ca\\\/tolerability\\\/\",\"name\":\"Safety and tolerability of vwd treatment\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/wilate.com\\\/ca\\\/#website\"},\"datePublished\":\"2022-04-05T13:15:46+00:00\",\"dateModified\":\"2022-12-22T13:36:19+00:00\",\"description\":\"Treatment with von Willebrand factor concentrates is generally well tolerated. No thromboembolic events or inhibitory antibodies haven been reported.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/wilate.com\\\/ca\\\/tolerability\\\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/wilate.com\\\/ca\\\/tolerability\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/wilate.com\\\/ca\\\/tolerability\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/wilate.com\\\/ca\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tolerability\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/wilate.com\\\/ca\\\/#website\",\"url\":\"https:\\\/\\\/wilate.com\\\/ca\\\/\",\"name\":\"WILATE CA\",\"description\":\"Putting you in control of von Willebrand disease\",\"publisher\":{\"@id\":\"https:\\\/\\\/wilate.com\\\/ca\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/wilate.com\\\/ca\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/wilate.com\\\/ca\\\/#organization\",\"name\":\"WILATE CA\",\"url\":\"https:\\\/\\\/wilate.com\\\/ca\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\\\/\\\/wilate.com\\\/ca\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/wilate.com\\\/ca\\\/wp-content\\\/uploads\\\/sites\\\/5\\\/2022\\\/03\\\/Wilate-logo-untertitel@2x-padding.png\",\"contentUrl\":\"https:\\\/\\\/wilate.com\\\/ca\\\/wp-content\\\/uploads\\\/sites\\\/5\\\/2022\\\/03\\\/Wilate-logo-untertitel@2x-padding.png\",\"width\":504,\"height\":202,\"caption\":\"WILATE CA\"},\"image\":{\"@id\":\"https:\\\/\\\/wilate.com\\\/ca\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Safety and tolerability of vwd treatment","description":"Treatment with von Willebrand factor concentrates is generally well tolerated. No thromboembolic events or inhibitory antibodies haven been reported.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/wilate.com\/ca\/tolerability\/","og_locale":"en_GB","og_type":"article","og_title":"Safety and tolerability of vwd treatment","og_description":"Treatment with von Willebrand factor concentrates is generally well tolerated. No thromboembolic events or inhibitory antibodies haven been reported.","og_url":"https:\/\/wilate.com\/ca\/tolerability\/","og_site_name":"WILATE CA","article_modified_time":"2022-12-22T13:36:19+00:00","twitter_card":"summary_large_image","twitter_misc":{"Estimated reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/wilate.com\/ca\/tolerability\/","url":"https:\/\/wilate.com\/ca\/tolerability\/","name":"Safety and tolerability of vwd treatment","isPartOf":{"@id":"https:\/\/wilate.com\/ca\/#website"},"datePublished":"2022-04-05T13:15:46+00:00","dateModified":"2022-12-22T13:36:19+00:00","description":"Treatment with von Willebrand factor concentrates is generally well tolerated. No thromboembolic events or inhibitory antibodies haven been reported.","breadcrumb":{"@id":"https:\/\/wilate.com\/ca\/tolerability\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/wilate.com\/ca\/tolerability\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/wilate.com\/ca\/tolerability\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/wilate.com\/ca\/"},{"@type":"ListItem","position":2,"name":"Tolerability"}]},{"@type":"WebSite","@id":"https:\/\/wilate.com\/ca\/#website","url":"https:\/\/wilate.com\/ca\/","name":"WILATE CA","description":"Putting you in control of von Willebrand disease","publisher":{"@id":"https:\/\/wilate.com\/ca\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/wilate.com\/ca\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-GB"},{"@type":"Organization","@id":"https:\/\/wilate.com\/ca\/#organization","name":"WILATE CA","url":"https:\/\/wilate.com\/ca\/","logo":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/wilate.com\/ca\/#\/schema\/logo\/image\/","url":"https:\/\/wilate.com\/ca\/wp-content\/uploads\/sites\/5\/2022\/03\/Wilate-logo-untertitel@2x-padding.png","contentUrl":"https:\/\/wilate.com\/ca\/wp-content\/uploads\/sites\/5\/2022\/03\/Wilate-logo-untertitel@2x-padding.png","width":504,"height":202,"caption":"WILATE CA"},"image":{"@id":"https:\/\/wilate.com\/ca\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/wilate.com\/ca\/wp-json\/wp\/v2\/pages\/6342","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/wilate.com\/ca\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/wilate.com\/ca\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/wilate.com\/ca\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/wilate.com\/ca\/wp-json\/wp\/v2\/comments?post=6342"}],"version-history":[{"count":397,"href":"https:\/\/wilate.com\/ca\/wp-json\/wp\/v2\/pages\/6342\/revisions"}],"predecessor-version":[{"id":12865,"href":"https:\/\/wilate.com\/ca\/wp-json\/wp\/v2\/pages\/6342\/revisions\/12865"}],"wp:attachment":[{"href":"https:\/\/wilate.com\/ca\/wp-json\/wp\/v2\/media?parent=6342"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}